Viking Therapeutics Inc
VKTX
Company Profile
Business description
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Contact
9920 Pacific Heights Boulevard
Suite 350
San DiegoCA92121
USAT: +1 858 704-4660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
53
Stocks News & Analysis
stocks
Strong results from cheap ASX share
The market responded favourably to results but shares still underpriced.
stocks
Anthropic’s Claude code security release is not bad news for cyber stocks
We believe cyber vendors will be able to adopt LLM’s for their benefit.
stocks
Earnings losers: TWE, GMG, SUN and more fall on weaker profits
Where companies fell short of market expectations in the third week of earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,244.30 | 16.50 | -0.18% |
| CAC 40 | 8,523.14 | 124.36 | 1.48% |
| DAX 40 | 24,991.97 | 268.72 | -1.06% |
| Dow JONES (US) | 48,804.06 | 821.91 | -1.66% |
| FTSE 100 | 10,707.12 | 20.23 | 0.19% |
| HKSE | 26,500.57 | 581.34 | -2.15% |
| NASDAQ | 22,627.27 | 258.79 | -1.13% |
| Nikkei 225 | 57,396.46 | 570.76 | 1.00% |
| NZX 50 Index | 13,532.31 | 111.88 | 0.83% |
| S&P 500 | 6,837.75 | 71.76 | -1.04% |
| S&P/ASX 200 | 9,022.30 | 12.10 | -0.13% |
| SSE Composite Index | 4,120.38 | 38.30 | 0.94% |